ESSA Pharma Completes Acquisition by XenoTherapeutics for Future Growth

Author: Hannah Lewis Updated: 10-09-2025 07:26 AM

ESSA Pharma Completes XenoTherapeutics Acquisition

ESSA Pharma Inc. (NASDAQ: EPIX) has recently finalized its acquisition by XenoTherapeutics. This strategic move aims to enhance the capabilities of both companies in their respective fields of research and development.

Details of the Acquisition

Xeno Acquisition Corp., a subsidiary of XenoTherapeutics, acquired all outstanding common shares of ESSA for about US$0.1242 per share. In addition to this price, each share comes with a contingent value right (CVR), offering potential payments of up to US$0.14 per CVR, depending on certain conditions post-acquisition. This could mean a significant aggregate potential payout of about US$6.7 million to eligible CVR holders.

Approval and Final Steps

On October 7, 2025, the Supreme Court of British Columbia granted approvals for the acquisition process. Subsequently, ESSA has initiated the delisting process with the Nasdaq Capital Market, informing them of its decision to terminate the registration of its common shares. This termination is expected to be finalized approximately ten days after the acquisition closes.

Advisors for the Transaction

For this significant acquisition, ESSA received expert guidance. Leerink Partners LLC acted as the exclusive financial advisor, while Blake, Cassels & Graydon, LLP and Skadden, Arps, Slate, Meagher & Flom LLP provided Canadian and U.S. legal counsel respectively.

About ESSA Pharma Inc.

ESSA Pharma has established itself in the pharmaceutical landscape with a focus on cutting-edge therapies aimed at treating prostate cancer. The company stands at the forefront of developing novel medical solutions that cater to a significant patient demographic.

Continuing Impact in Research

The newly formed alliance with XenoTherapeutics marks a new chapter in ESSA's journey, empowering it to advance research and broaden its therapeutic offerings. This partnership promises to leverage the strengths of both organizations to optimize treatment innovations.

About XenoTherapeutics, Inc.

XenoTherapeutics operates as a research foundation concentrating on the scientific progress of xenotransplantation. Its mission includes research, clinical developments, and public education, striving to pave the way for breakthroughs in medical treatments.

Frequently Asked Questions

1. What is the significance of the acquisition?

The acquisition allows ESSA Pharma to enhance its research capabilities and broaden its therapeutic areas, particularly in prostate cancer treatment and related fields.

2. How will this affect the stock of ESSA Pharma?

The delisting from Nasdaq may impact stock valuations temporarily, but the acquisition aims to position the company for future growth and stability.

3. What are contingent value rights (CVRs)?

CVRs are a form of financial right that entitles shareholders to certain payments depending on defined conditions—here, based on the future success of the acquisition.

4. Who are the primary advisors for this acquisition?

Leerink Partners LLC served as the financial advisor, while two law firms provided necessary legal counsel for both Canadian and U.S. regulations.

5. What can be expected from ESSA post-acquisition?

Post-acquisition, ESSA is expected to focus on expanding its research capabilities and potentially introducing innovative therapies, leveraging its partnership with XenoTherapeutics.

About The Author

Hi there, I'm Hannah Lewis, a writer and financial specialist of 36 years old committed to making money understandable and approachable to everyone. Years of working in the field have given me a thorough grasp of market trends, investment techniques, and economic fundamentals. My objective is to enable people, by means of understandable, useful guidance, to take charge of their financial destiny.

I have written many articles for financial blogs over my career that simplify difficult financial ideas into understandable insights. Being financially literate is a critical ability, and I am passionate about enabling people to confidently manage their financial lives. Regardless of your level of experience, my work will help you at every stage of the investment process. I appreciate being allowed to share in your success and financial expansion.

Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.